Cosopt Versus Xalatan

To compare the 24-hour efficacy and safety, measured every three hours, of the dorzolamide/timolol fixed combination given twice daily versus latanoprost and placebo each given once daily.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Open-angle Glaucoma Eye Diseases Glaucoma Glaucoma, Open-Angle Ocular Hypertension

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Central Florida Eye Associates, Lakeland, Florida, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

adults with primary open-angle, pigmentary, or exfoliation glaucoma, or ocular hypertenstion
intraocular pressure should be 22 to 30 mm Hg inclusive on timolol BID at the 08:00 H
ETDRS visual acuity must be 1.0 or better in both eyes

Exclusion criteria

any contraindications to study medications
any anticipated change in systemic hypertensive therapy during the trial

Treatment and study plan

timolol maleate 0.5%

Drug

dorzolamide/timolol maleate fixed combination

Drug

Latanoprost 0.005%

Drug

Placebo

Drug

Sponsors and collaborators

Lead sponsor

Pharmaceutical Research Network

Other

Registry information

Important dates

Study start: 2005
Study completion: 2005
First posted: Jan 9, 2006
Registry last updated: Jan 9, 2007

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed